|
US20030091630A1
(en)
*
|
2001-10-25 |
2003-05-15 |
Jenny Louie-Helm |
Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
|
|
US20030152622A1
(en)
*
|
2001-10-25 |
2003-08-14 |
Jenny Louie-Helm |
Formulation of an erodible, gastric retentive oral diuretic
|
|
CA2480826C
(fr)
|
2002-04-09 |
2012-02-07 |
Flamel Technologies |
Formulation pharmaceutique orale sous forme de suspension aqueuse de microcapsules permettant la liberation modifiee de principe(s) actif(s)
|
|
MXPA05007381A
(es)
|
2003-01-13 |
2006-02-10 |
Dynogen Pharmaceuticals Inc |
Metodo para el tratamiento de transtornos funcionales del intestino.
|
|
SI1589966T1
(sl)
*
|
2003-01-30 |
2011-06-30 |
Lek Pharmaceuticals D.D. |
Postopek čiščenja losartana
|
|
MXPA05008142A
(es)
*
|
2003-01-31 |
2005-09-30 |
Sankyo Co |
Medicamento para la profilaxis y el tratamiento de arteriosclerosis e hipertension.
|
|
EP1750717B1
(en)
*
|
2004-02-11 |
2017-07-19 |
Rubicon Research Private Limited |
Controlled release pharmaceutical compositions with improved bioavailability
|
|
US7838552B2
(en)
*
|
2004-06-04 |
2010-11-23 |
Forest Laboratories Holdings Limited |
Compositions comprising nebivolol
|
|
WO2006046528A1
(ja)
*
|
2004-10-29 |
2006-05-04 |
Kowa Co., Ltd. |
糸球体疾患治療剤
|
|
FR2884145A1
(fr)
*
|
2005-04-06 |
2006-10-13 |
Flamel Technologies Sa |
Forme pharmaceutique orale de losartan
|
|
JP2008530185A
(ja)
*
|
2005-02-21 |
2008-08-07 |
フラメル・テクノロジー |
ロサルタンの経口医薬剤形態
|
|
FR2882260A1
(fr)
*
|
2005-02-21 |
2006-08-25 |
Flamel Technologies Sa |
Forme pharmaceutique orale multimicroparticulaire a liberation modifiee d'antagonistes des recepteurs de l'angiotensine ii
|
|
CA2613417C
(en)
*
|
2005-06-27 |
2011-11-29 |
Daiichi Sankyo Company, Limited |
Pharmaceutical preparation containing an angiotensin ii receptor antagonist and a calcium channel blocker
|
|
DE102005031577A1
(de)
|
2005-07-06 |
2007-01-11 |
Bayer Healthcare Ag |
Pharmazeutische Darreichungsformen enthaltend eine Wirkstoffkombination von Nifedipin und/oder Nisoldipin und einem Angiotensin-II Antagonisten
|
|
AU2006329564A1
(en)
|
2005-07-11 |
2007-07-05 |
Pharmena North America Inc. |
Formulations for treatment of lipoprotein abnormalities comprising a statin a statin and a methylnicotinamide derivative
|
|
TWI399223B
(zh)
*
|
2006-09-15 |
2013-06-21 |
Daiichi Sankyo Co Ltd |
奧美沙坦酯及氨氯地平之固體劑型
|
|
KR100888131B1
(ko)
*
|
2006-10-10 |
2009-03-11 |
한올제약주식회사 |
시간차 투약 원리를 이용한 심혈관계 질환 치료용 복합제제
|
|
WO2009084040A1
(en)
*
|
2007-12-28 |
2009-07-09 |
Rubicon Research Private Limited |
Once a day formulation of angiotensin receptor blockers
|
|
US8377453B2
(en)
|
2008-03-11 |
2013-02-19 |
Depomed, Inc. |
Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
|
|
US8372432B2
(en)
|
2008-03-11 |
2013-02-12 |
Depomed, Inc. |
Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
|
|
US20110117194A1
(en)
|
2008-04-29 |
2011-05-19 |
Hanall Biopharma Co., Ltd. |
Pharmaceutical formulation containing angiotensin-ii receptor blocker
|
|
TW201014850A
(en)
|
2008-09-25 |
2010-04-16 |
Takeda Pharmaceutical |
Solid pharmaceutical composition
|
|
DE102008059206A1
(de)
|
2008-11-27 |
2010-06-10 |
Bayer Schering Pharma Aktiengesellschaft |
Pharmazeutische Darreichungsform enthaltend Nifedipin oder Nisoldipin und einen Angiotensin-II Antagonisten und/oder ein Diuretikum
|
|
EP2427243A4
(en)
|
2009-05-05 |
2012-11-21 |
Vapogenix Inc |
NEW FORMULATIONS OF VOLATILE ANESTHETICS AND METHOD OF ADMINISTRATION
|
|
US9198861B2
(en)
|
2009-12-22 |
2015-12-01 |
Mallinckrodt Llc |
Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
|
|
US8597681B2
(en)
|
2009-12-22 |
2013-12-03 |
Mallinckrodt Llc |
Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
|
|
EP2392318A1
(en)
|
2010-05-21 |
2011-12-07 |
Laboratorios Liconsa, S.A. |
A pharmaceutical controlled release composition of losartan
|
|
CN103347517B
(zh)
|
2010-08-11 |
2018-10-02 |
德雷克塞尔大学 |
治疗帕金森病中运动障碍的d3多巴胺受体激动剂
|
|
JP6076913B2
(ja)
|
2010-12-07 |
2017-02-08 |
ドレクセル ユニバーシティ |
癌からの転移を阻害する方法
|
|
US8476221B2
(en)
|
2011-03-18 |
2013-07-02 |
Halimed Pharmaceuticals, Inc. |
Methods and compositions for the treatment of metabolic disorders
|
|
US8741885B1
(en)
|
2011-05-17 |
2014-06-03 |
Mallinckrodt Llc |
Gastric retentive extended release pharmaceutical compositions
|
|
US8858963B1
(en)
|
2011-05-17 |
2014-10-14 |
Mallinckrodt Llc |
Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
|
|
US9050335B1
(en)
|
2011-05-17 |
2015-06-09 |
Mallinckrodt Llc |
Pharmaceutical compositions for extended release of oxycodone and acetaminophen resulting in a quick onset and prolonged period of analgesia
|
|
US20130143867A1
(en)
|
2011-12-02 |
2013-06-06 |
Sychroneuron Inc. |
Acamprosate formulations, methods of using the same, and combinations comprising the same
|
|
WO2013096744A1
(en)
|
2011-12-21 |
2013-06-27 |
Novira Therapeutics, Inc. |
Hepatitis b antiviral agents
|
|
CA2872542A1
(en)
|
2012-05-07 |
2013-11-14 |
Bayer Pharma Aktiengesellschaft |
Process for manufacturing a pharmaceutical dosage form comprising nifedipine and candesartan cilexetil
|
|
CA2879454A1
(en)
|
2012-07-19 |
2014-01-23 |
Drexel University |
Novel sigma receptor ligands and methods of modulating cellular protein homeostasis using same
|
|
EP3378472A1
(en)
|
2012-08-09 |
2018-09-26 |
Dynamis Therapeutics, Inc. |
Combinations of meglumine
|
|
PT2941233T
(pt)
|
2013-01-07 |
2020-11-13 |
Univ Pennsylvania |
Composições e métodos para tratar linfoma cutâneo de células t
|
|
WO2014197744A1
(en)
|
2013-06-05 |
2014-12-11 |
Synchroneuron, Inc. |
Acamprosate formulations, methods of using the same, and combinations comprising the same
|
|
RU2673737C2
(ru)
|
2013-07-02 |
2018-11-29 |
ЭКОПЛЭНЕТ ЭНВАЙРОНМЕНТАЛ, ЭлЭлСи |
Композиции летучих органических веществ, обладающие антимикробной активностью
|
|
GB201311891D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compound
|
|
GB201311888D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
|
WO2015028972A1
(en)
|
2013-09-02 |
2015-03-05 |
Ranbaxy Laboratories Limited |
Pulsatile-release dosage form
|
|
WO2015080943A1
(en)
|
2013-11-26 |
2015-06-04 |
Yale University |
Novel cell-penetrating compositions and methods using same
|
|
EP3077401B1
(en)
*
|
2013-12-06 |
2018-04-18 |
Genentech, Inc. |
Serine/threonine kinase inhibitors
|
|
EP3079692A4
(en)
|
2013-12-09 |
2017-10-18 |
Thomas Jefferson University |
Novel methods of treating a neurodegenerative disease in a mammal in need thereof
|
|
EP3128996B1
(en)
|
2014-04-07 |
2021-06-02 |
University of Rochester |
Novel 7-dehydrocholesterol derivatives and methods using same
|
|
US20180228907A1
(en)
|
2014-04-14 |
2018-08-16 |
Arvinas, Inc. |
Cereblon ligands and bifunctional compounds comprising the same
|
|
EP3182979B1
(en)
|
2014-08-20 |
2023-12-06 |
Yale University |
Novel compositions and methods useful for treating or preventing liver diseases or disorders, and promoting weight loss
|
|
WO2016182968A1
(en)
|
2015-05-08 |
2016-11-17 |
Brown University |
Novel syringolin analogues and methods of making and using same
|
|
KR20250078598A
(ko)
|
2015-05-19 |
2025-06-02 |
예일 유니버시티 |
병리학적 석회화 병태를 치료하기 위한 조성물, 및 이의 사용 방법
|
|
US10829440B2
(en)
|
2015-06-12 |
2020-11-10 |
Brown University |
Antibacterial compounds and methods of making and using same
|
|
WO2017003822A1
(en)
|
2015-06-30 |
2017-01-05 |
Galleon Pharmaceuticals, Inc. |
Novel breathing control modulating compounds, and methods of making and using same
|
|
EA201890346A1
(ru)
*
|
2015-07-29 |
2018-08-31 |
Такеда Гмбх |
Ингибитор pdf4 для лечения диабетической нефропатии
|
|
EP3368505B1
(en)
|
2015-10-28 |
2023-02-22 |
Yale University |
Quinoline amides and methods of using same
|
|
WO2017087936A1
(en)
|
2015-11-20 |
2017-05-26 |
Yale University |
Compositions for treating ectopic calcification disorders, and methods using same
|
|
US9675585B1
(en)
|
2016-03-24 |
2017-06-13 |
Ezra Pharma |
Extended release pharmaceutical formulations
|
|
US9687475B1
(en)
|
2016-03-24 |
2017-06-27 |
Ezra Pharma Llc |
Extended release pharmaceutical formulations with controlled impurity levels
|
|
EP3448369B1
(en)
|
2016-04-29 |
2025-06-25 |
The Regents of The University of Colorado, A Body Corporate |
Inhibition or degradation of hdac11 for treating obesity, hyperlipidemia, type ii diabetes, metabolic syndrome or insulin resistance, for promoting weight loss, and/or ameliorating or preventing weight gain
|
|
US20210330599A1
(en)
|
2016-08-01 |
2021-10-28 |
University Of Rochester |
Nanoparticles for Controlled Release of Anti-Biofilm Agents and Methods of Use
|
|
BR112019002355A2
(pt)
|
2016-08-05 |
2019-07-16 |
Yale University |
composições e métodos para prevenção de acidente vascular cerebral em pacientes pediátricos com anemia falciforme
|
|
EP3506983B1
(en)
|
2016-09-01 |
2021-08-25 |
Mebias Discovery, Inc. |
Substituted urea-derivatives for the treatment of pain
|
|
TWI794190B
(zh)
|
2016-11-07 |
2023-03-01 |
加拿大商愛彼特生物製藥公司 |
含有取代的吡啶酮之三環化合物及其使用方法
|
|
EP3571196B1
(en)
|
2017-01-19 |
2023-01-04 |
Temple University Of The Commonwealth System Of Higher Education |
Novel bridged bicycloalkyl-substituted aminothizoles and their methods of use
|
|
AU2018238138A1
(en)
|
2017-03-21 |
2019-10-17 |
Arbutus Biopharma Corporation |
Substituted dihydroindene-4-carboxamides and analogs thereof, and methods using same
|
|
JP7108018B2
(ja)
|
2017-04-17 |
2022-07-27 |
イエール ユニバーシティ |
急性肺傷害を処置または予防する化合物、組成物および方法
|
|
EP3659307A4
(en)
|
2017-07-28 |
2021-09-22 |
Yale University |
ANTI-CANCER PRODUCTS AND METHOD FOR MANUFACTURING AND USING THEREOF
|
|
SG11202002060XA
(en)
|
2017-09-08 |
2020-04-29 |
Univ Colorado Regents |
Compounds, compositions and methods for treating or preventing her-driven drug-resistant cancers
|
|
US20200323895A1
(en)
|
2017-11-27 |
2020-10-15 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic |
Compounds, Compositions, and Methods for Treating And/Or Preventing Periodontal Disease
|
|
WO2019126214A1
(en)
|
2017-12-18 |
2019-06-27 |
Tris Pharma, Inc. |
Pharmaceutical composition comprising ghb gastro-retentive raft forming systems having trigger pulse drug release
|
|
US11337919B2
(en)
|
2017-12-18 |
2022-05-24 |
Tris Pharma, Inc. |
Modified release drug powder composition comprising gastro-retentive RAFT forming systems having trigger pulse drug release
|
|
EP3737353A1
(en)
|
2017-12-18 |
2020-11-18 |
Tris Pharma, Inc. |
Ghb pharmaceutical compositions comprising a floating interpenetrating polymer network forming system
|
|
WO2019126216A1
(en)
|
2017-12-18 |
2019-06-27 |
Tris Phama, Inc. |
Pharmaceutical compositions comprising a floating interpenetrating polymer network forming system
|
|
WO2019125184A1
(en)
|
2017-12-19 |
2019-06-27 |
Auckland Uniservices Limited |
Use of biomarker in cancer therapy
|
|
CA3089236A1
(en)
|
2018-01-24 |
2019-08-01 |
The Rockefeller University |
Antibacterial compounds, compositions thereof, and methods using same
|
|
CA3101680A1
(en)
|
2018-05-25 |
2019-11-28 |
Temple University-Of The Commonwealth System Of Higher Education |
Eradication of bacterial biofilm using anti-amyloid monoclonal antibodies
|
|
AU2019279761A1
(en)
|
2018-05-29 |
2020-12-10 |
Cersci Therapeutics, Inc. |
Compounds for pain treatment, compositions comprising same, and methods of using same
|
|
TWI869058B
(zh)
|
2018-07-27 |
2025-01-01 |
加拿大商愛彼特生物製藥公司 |
經取代四氫環戊[c]吡咯、經取代二氫吡咯，其類似物及使用其之方法
|
|
CA3109798A1
(en)
|
2018-08-17 |
2020-02-20 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for treatment of acute lung injury
|
|
AU2018445164B2
(en)
|
2018-10-11 |
2025-05-29 |
Vifor (International) Ltd. |
Inositol phosphates for the treatment of ectopic calcification
|
|
US12458601B2
(en)
|
2018-10-19 |
2025-11-04 |
Temple University-Of The Commonwealth System Of Higher Education |
Tamper-resistant drug dosage forms and methods of making and use thereof
|
|
TW202415643A
(zh)
|
2018-12-12 |
2024-04-16 |
加拿大商愛彼特生物製藥公司 |
經取代之芳基甲基脲類及雜芳基甲基脲類、其類似物及其使用方法
|
|
CN113365636A
(zh)
|
2019-01-30 |
2021-09-07 |
萨尼菲特治疗有限公司 |
用于增加组织灌注的磷酸肌醇化合物
|
|
WO2020159565A1
(en)
|
2019-02-01 |
2020-08-06 |
Cersci Therapeutics, Inc. |
Methods of treating post-surgical pain with a thiazoline anti-hyperalgesic agent
|
|
US20200246317A1
(en)
|
2019-02-01 |
2020-08-06 |
Cersci Therapeutics, Inc. |
Methods of treating diabetic neuropathy with a thiazoline anti-hyperalgesic agent
|
|
WO2020210697A1
(en)
|
2019-04-12 |
2020-10-15 |
Sdg, Inc. |
Lipid-based nanoparticles and use of same in optimized insulin dosing regimens
|
|
IL287617B2
(en)
|
2019-05-09 |
2024-11-01 |
Feinstein Institutes For Medical Research |
Hmgb1 antagonist
|
|
WO2020252407A1
(en)
|
2019-06-12 |
2020-12-17 |
The Wistar Institute |
Acetyl-coa synthetase 2 (acss2) inhibitors and methods using same
|
|
US11555010B2
(en)
|
2019-07-25 |
2023-01-17 |
Brown University |
Diamide antimicrobial agents
|
|
EP3818983A1
(en)
|
2019-11-11 |
2021-05-12 |
Sanifit Therapeutics S.A. |
Inositol phosphate compounds for use in treating, inhibiting the progression, or preventing cardiovascular calcification
|
|
WO2021127456A1
(en)
|
2019-12-19 |
2021-06-24 |
Rain Therapeutics Inc. |
Methods of inhibiting epidermal growth factor receptor proteins
|
|
IL298853A
(en)
|
2020-06-09 |
2023-02-01 |
Inozyme Pharma Inc |
Soluble enpp1 or enpp3 proteins and uses thereof
|
|
EP4216949A4
(en)
|
2020-09-28 |
2024-12-11 |
Yale University |
Selective agonists of 5-ht2a receptor and methods of use
|
|
EP4015494A1
(en)
|
2020-12-15 |
2022-06-22 |
Sanifit Therapeutics S.A. |
Processes for the preparation of soluble salts of inositol phosphates
|
|
EP4036097A1
(en)
|
2021-01-29 |
2022-08-03 |
Sanifit Therapeutics S.A. |
Ip4-4,6 substituted derivative compounds
|
|
TW202412815A
(zh)
|
2022-07-29 |
2024-04-01 |
西班牙商薩尼菲特治療公司 |
Ip5經取代化合物
|
|
CA3263498A1
(en)
|
2022-07-29 |
2024-02-01 |
Vifor (International) Ltd. |
IP4-4,6 SUBSTITUTED DERIVATIVE COMPOUNDS INTENDED FOR USE IN THE TREATMENT, INHIBITION OF PROGRESSION AND PREVENTION OF ECTOPIC CALCIFICATION
|
|
US20260083759A1
(en)
|
2022-09-06 |
2026-03-26 |
Hadasit Medical Research Services And Development Ltd |
Combinations Comprising Psychedelics for the Treatment of Schizophrenia and Other Neuropsychiatric and Neurologic Disorders
|
|
WO2024163966A1
(en)
|
2023-02-03 |
2024-08-08 |
Tris Pharma, Inc. |
Low sodium oxybate once nightly composition
|
|
CN121729233A
(zh)
|
2023-08-14 |
2026-03-24 |
纽瑞姆制药（1991）有限公司 |
Gal475组合物及其使用方法
|
|
WO2025162971A1
(en)
|
2024-01-31 |
2025-08-07 |
Sanifit Therapeutics, S.A. |
Substituted ip5 compounds for use in the treatment, inhibition of progression, and prevention of ectopic calcification
|
|
WO2025217094A1
(en)
|
2024-04-08 |
2025-10-16 |
University Of Rochester |
Interleukin receptor-associated kinase (irak) protac degraders and medical use thereof
|
|
WO2025217096A1
(en)
|
2024-04-08 |
2025-10-16 |
University Of Rochester |
Inhibitors of leucine-rich repeat kinase 2 (lrrk2) and medical uses thereof
|
|
WO2025217379A1
(en)
|
2024-04-10 |
2025-10-16 |
University Of Rochester |
Drug treatment for macular degeneration
|
|
WO2026050206A1
(en)
|
2024-08-27 |
2026-03-05 |
Ironwood Pharmaceuticals, Inc. |
Combinations of glp-1 and guanylate cyclase c (gc-c) receptor agonists
|